Skip to main content

Table 1 Different doxycycline treatment schemes, including duration of treatment, concentrations and mice models used

From: Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models

Treatment period

Dose (mg/Kg/day)

strain

Age (months)

Treatment MMP-9 positive

Control MMP-9 positive

Treatment CR positive

Control CR positive

1 month

40

TTR/HSF

19

2/10

6/8

0/10

5/10

15 days

40

TTR/HSF

26

2/10

7/8

2/10

3/7

15 days + 45 days interruption

40

TTR/HSF

20

8/10

6/8

5/10

4/8

15 days + 30 days interruption

40

TTR/HSF

23-25

0/10

10/10

0/10

8/10

15 days

8

TTR/HSF

16-18

1/7

9/10

1/7

8/10

15 days + 30 days interruption

8

TTR/HSF

16-18

8/12

4/4

7/12

3/7

15 days + 15 days interruption

8

TTR/HSF

20

4/10

7/8

1/10

4/8

15 days + 15 days interruption

8

TTR

22

2/15

6/8

2/15

4/8

  1. Ratios between the number of animals which showed positive staining for MMP-9 and CR and the total number of mice used in each group are shown.